You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company also projected full year 2020 revenue of between $84 million and 86 million and said that its instrument install base grew 34 percent over the year.
Under the agreements, Bioké, a business unit of Cell Signaling Technology Europe, will distribute the two platforms in the Netherlands, Belgium, and Luxembourg.
Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.
Two recently released preprints highlight new approaches to single-cell proteomics, including one making use of a modified version of Bruker's timsTOF Pro.
Seer will be able to offer its Proteograph Product Suite for sale with several of the two companies' mass spectrometers.
The approach is able to look at structure and function across large numbers of proteins, adding data beyond traditional expression-based measurements.
The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
The firm will use funds from the round, which consists of $85 million in equity securities and a $50 million credit facility, to expand global sales and production.
New cellular and molecular spatial biology methods, companies, and product offerings have made this area one of the hottest in the life science market.
Cowen highlighted the company's potential for allowing proteomics experiments at scale, allowing for deep proteomic measurements at high throughput.
The company is looking to grow uptake of its products in a variety of life science markets ranging from toxicology testing to biopharma research.
The funding adds to a $121 million raise the company announced last month and will go towards expanding and commercializing its SomaScan platform.
The firm is placing systems with at least two research collaborators and plans to target six to 10 early-access customers for its ProteoGraph platform in 2021.
The company said that it plans to use the funds for facilities and equipment needed to scale up operation of its KScan phosphoproteomic platform.
In a recent study, the researchers examined the conditions under which carrier proteome-based single-cell workflows offered the best quantitative performance.
Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.
Shares of the Redwood City, California-based company will begin trading on the Nasdaq today under ticker symbol SEER at $19 per share.
Called diaPASEF, the method uses the ion trapping function of the timsTOF instrument to enable more efficient sampling of peptide precursor ions.
The spatial molecular imager will be NanoString's next play in a growing market that it says is worth more than $12 billion, including diagnostic applications.
The company plans to use proceeds from the round to further commercialize products based on its mass spec multinozzle emitter array (MEA) technology.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.